Day

October 22, 2024
Knowledge and Empowerment
Self advocating allows the knowledgeable CML patient to become a highly engaged patient.  Studies have shown that engaged patients may have a higher success rate of achieving better results with their overall health care (ref 1.) We have developed some very cool tools to help you get started towards your own journey of empowerment. Click...
Read More
servey
Muchas gracias por tomarse el tiempo para completar la encuesta! Importancia de esta investigación Esta investigación es importante porque ayuda a mejorar nuestra comprensión de la experiencia del paciente en términos de calidad de vida mientras que reciben tratamiento para la Leucemia mieloide crónica Beneficios y puede ayudar a crear o perfeccionar programas o planes de tratamiento...
Read More
Myelofibrosis
Like CML, Myelofibrosis (MF) is another rare disorder in the family of Myeloproliferative Neoplasms (MPN’s). The CML Society of Canada is expanding our reach to provide support to patients with MF and to help them find a voice of their own, while being supported with our voices. The incidence of MF in Canada is very rare,...
Read More
Myelofibrosis
 Overview Myelofibrosis (MF) is a life-threatening blood cancer associated with progressive, debilitating symptoms that can severely impact quality of life and shorten survival.[i],[ii]  MF is characterized by bone marrow scarring (fibrosis), an enlarged spleen (splenomegaly) and debilitating consequences, including fatigue, fever, night sweats, itchy skin, bone pain, abdominal pain or discomfort, and weight loss.[iii],[iv] MF...
Read More
Myelofibrosis
provincial coverage Click on the map below for information regarding government reimbursement in your province. Other coverage Private Insurance Special Access Programs Clinical trial Alberta Jakavi (ruxolitinib) Company: Novartis Canada Coverage: Yes Type of coverage:For patients with intermediate to high risk symptomatic For patients with intermediate to high risk symptomaticMyelofibrosis (MF) as assessed using the DynamicInternational...
Read More
cml innovation
We are a strong team of innovative, strategically minded and knowledgeable patients.  We have used our talents to create some innovative tools and awareness campaigns to improve the lives of our fellow CML patients. To read the story behind some of our most creative ideas, click on the links below: Awareness – CML Awareness Day...
Read More
Patented Medicines
Today, Health Canada took an important step forward in an effort to bring a National Pharmacare program to all Canadians.  The long awaited for, and necessary changes, to the PMPRB were announced.   We are pleased to have worked with a core group of independent patient advocates to support the government’s changes to  the PMPRB. NEWS...
Read More
PCR
The CML Society of Canada, along with our partners, are pleased to announce the launch of our latest Patient Navigational Tool PCR TRACKER – Specifically engineered for CML Patients – By CML Patients √ Track and Graph results from lab tests such as CBC, blood chemistry, FISH and PCR √ Personalize program to help me to remember...
Read More
Polymerase Chain Reaction
Polymerase Chain Reaction (PCR) It is a scientific technique from the branch of molecular biology that allows us to amplify DNA segments.  We think it is much easier if you think of it as the specialized “photocopier” of your DNA. Polymerase – it is an enzyme.  It’s primary function is to polymerize new DNA or...
Read More
Medical Tests - Blood Test
This privacy statement explains our practices governing information obtained for continuing medical education courses. Privacy policies for other activities conducted online are addressed in our general Online Privacy Policy. Our Commitment to PrivacyData CollectionData UseYour OptionsAccessData SecurityContact Us Our Commitment To PrivacyThe CML Society of Canada (hereinafter “CML”) respects the privacy of every individual who...
Read More
1 2 3 4 5 6 8

Recent Articles

ACCESS TO AFFORDABLE MEDICINE FOR ALL
CML Access to Medicine
22 October 2024
APO-IMATINIB
Apo – imatinib – Treatment for CML
22 October 2024
ASH 2013
ASH 2013 – Newsletter
22 October 2024

Text Widget

Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Donec sed odio dui. Etiam porta sem malesuada.

Our Services